Monogram Orthopaedics Inc (MGRM)

Currency in USD
6.000
0.000(0.00%)
Closed·
Showing Monogram Orthopaedics historical data. For real-time data please try another search
Fair Value
Day's Range
5.8706.425
52 wk Range
2.3006.425
Key Statistics
Prev. Close
6
Open
6.1
Day's Range
5.87-6.425
52 wk Range
2.3-6.425
Volume
1.78M
Average Volume (3m)
423.84K
1-Year Change
150%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MGRM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Monogram Orthopaedics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Strong Sell
Moving Averages
Neutral

Monogram Technologies Inc. engages in developing surgical robot to enable placement of patient optimized orthopedic implants in the United States. It intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. The company was formerly known as Monogram Orthopaedics, Inc. and changed its name to Monogram Technologies Inc. in May 2024. Monogram Technologies Inc. was founded in 2015 and is headquartered in Austin, Texas. As of October 7, 2025, Monogram Technologies Inc. operates as a subsidiary of Zimmer Biomet Holdings, Inc.

Monogram Orthopaedics Inc Earnings Call Summary for Q1/2025

  • Monogram Orthopaedics' stock surged 8.8% after-hours following Q1 2025 results, with EPS forecast at -0.11
  • FDA clearance received for Emboss total TKA robotic surgical system; first live patient surgeries planned for summer/fall 2025
  • Strong cash position of $13.3M, no traditional debt; monthly cash burn reduced to $800K from $1.1M-$1.2M last year
  • Company aims to conduct world's first autonomous saw-based robotic total knee surgeries by summer/fall 2025
  • Analysts set price targets between $5.40-$6.00 per share; stock trading near Fair Value according to InvestingPro
Last Updated: 2025-05-14, 05:16 p/m
Read Full Transcript

Compare MGRM to Peers and Sector

Metrics to compare
MGRM
Peers
Sector
Relationship
P/E Ratio
0.0x−3.6x−0.4x
PEG Ratio
0.00−0.050.00
Price/Book
0.0x4.1x2.6x
Price / LTM Sales
0.0x3.2x3.1x
Upside (Analyst Target)
0.0%54.7%58.5%
Fair Value Upside
Unlock16.9%9.2%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-- / -0.11
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

MGRM Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.